Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.

Evans JD, Hill SR.

Patient Prefer Adherence. 2015 Aug 12;9:1159-64. doi: 10.2147/PPA.S56002. eCollection 2015. Review.

2.

Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.

Sung HH, Lee SW.

Korean J Urol. 2012 Jun;53(6):377-85. doi: 10.4111/kju.2012.53.6.377. Epub 2012 Jun 19.

3.

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.

Washington SL 3rd, Shindel AW.

Drug Des Devel Ther. 2010 Sep 7;4:159-71. Review.

4.

Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?

Vardi Y.

Diabetes Care. 2009 Nov;32 Suppl 2:S420-2. doi: 10.2337/dc09-S351. Review. No abstract available.

5.

Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Sadovsky R, Brock GB, Gutkin SW, Sorsaburu S.

Int J Clin Pract. 2009 Aug;63(8):1214-30. doi: 10.1111/j.1742-1241.2009.02119.x. Review.

6.

Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study.

Rosenberg MT, Adams PL, McBride TA, Roberts JN, McCallum SW.

Int J Clin Pract. 2009 Jan;63(1):27-34. doi: 10.1111/j.1742-1241.2008.01947.x.

7.

Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.

Frajese GV, Pozzi F, Frajese G.

Clin Interv Aging. 2006;1(4):439-49. Review.

8.

Tadalafil pharmacokinetics in healthy subjects.

Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI.

Br J Clin Pharmacol. 2006 Mar;61(3):280-8.

Items per page

Supplemental Content

Write to the Help Desk